Abstract: The invention relates to the surprising finding that biomarkers corresponding to ACAA1, AP1M2, CGN, DDR1, EPS8L2, FASTKD1, GMIP, IKBKE, P2RX4, P4HB, PHKG2, PPFIBP2, PPP1R16A, RASSF7, RNF183, SIRT6, TJP3, EFEMP2, SOCS2, and DCN are differentially expressed in control samples as compared to samples from patients having endometrial cancer and are therefore useful for detecting endometrial cancer. In particular these biomarkers having excellent sensitivity, specificity, and/or the ability to separate affected from non affected individuals. Furthermore, the inventors found that the differential expression of these biomarkers in primary endometrial cancer tumor tissue is correlated to their expression level in uterine fluid samples as compared to control values. Thus these biomarkers are robust in that they are found to be differentially expressed in several different types of samples from affected and individuals.

Abstract: The invention relates to methods and compositions for the treatment or prevention of diseases and disorders associated with myeloproliferative disorders. In particular, the invention relates to an LSD 1 inhibitor for use in treating or preventing Philadelphia chromosome negative myeloproliferative disorders.

Abstract: The invention relates to the surprising finding that biomarkers corresponding to ACAA1, AP1M2, CGN, DDR1, EPS8L2, FASTKD1, GMIP, IKBKE, P2RX4, P4HB, PHKG2, PPFIBP2, PPP1 R16A, RASSF7, RNF183, SIRT6, TJP3, EFEMP2, S0CS2, and DCN are differentially expressed in control samples as compared to samples from patients having endometrial cancer and are therefore useful for detecting endometrial cancer. In particular these biomarkers having excellent sensitivity, specificity, and/or the ability to separate affected from non affected individuals. Furthermore, the inventors found that the differential expression of these biomarkers in primary endometrial cancer tumor tissue is correlated to their expression level in uterine fluid samples as compared to control values. Thus these biomarkers are robust in that they are found to be differentially expressed in several different types of samples from affected individuals.

Abstract: The invention relates to methods and compositions for the treatment or prevention of inflammation and inflammatory diseases or conditions. In particular, the invention relates to an LSD1 inhibitor, such as a 2-cyclylcylopropan-1-amine derivative, a phenelzine derivative and a propargylamine derivative, for use in treating or preventing inflammation and inflammatory diseases or conditions.

Abstract: The invention relates to methods and compositions for the treatment or prevention of thrombosis, thrombus formation, a thrombotic event or complication, or a cardiovascular disease or event. In particular, the invention relates to an LSD inhibitor such as a 2-cyclylcyclopropan-1-amine derivative, a phenelzine derivative and a propargylamine derivative, for use in treating or preventing thrombosis, thrombus formation, a thrombotic event or complication, or a cardiovascular disease or event.

Abstract: The present invention relates to methods and compositions for the treatment or prevention of diseases and disorder associated with myeloproliferative and lymphoproliferative disorders. In particular, the invention relates to an LSD1 inhibitor for use in treating or preventing diseases and disorder associated with myeloproliferative and lymphoproliferative disorders.

Abstract: The invention relates to methods and compositions for the treatment or prevention of protein conformation disorders. In particular, the invention relates to an LSD1 inhibitor for use in treating or preventing a protein conformation disorder, such as, e.g., Huntington Disease.

Abstract: The invention relates to the surprising finding that biomarkers corresponding to ACAA1, AP1M2, CGN, DDR1, EPS8L2, FASTKD1, GMIP, IKBKE, P2RX4, P4HB, PHKG2, PPFIBP2, PPP1 R16A, RASSF7, RNF183, SIRT6, TJP3, EFEMP2, S0CS2, and DCN are differentially expressed in control samples as compared to samples from patients having endometrial cancer and are therefore useful for detecting endometrial cancer. In particular these biomarkers having excellent sensitivity, specificity, and/or the ability to separate affected from non affected individuals. Furthermore, the inventors found that the differential expression of these biomarkers in primary endometrial cancer tumor tissue is correlated to their expression level in uterine fluid samples as compared to control values. Thus these biomarkers are robust in that they are found to be differentially expressed in several different types of samples from affected individuals.

Abstract: The invention describes methods of molecular diagnosis of a concrete form of ?-synucleinopathy, the dementia with Lewy bodies (DLB), associated to the levels of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) or the alteration of its ubiquityl-ligase activity. It also refers to the use of compounds that permit the modification of the UCH-L1 levels or of the enzymatic activity of UCH-L1. This invention has application in the diagnosis and treatment of patients suffering from DLB.

Abstract: The treatment and prevention of neurodegenerative diseases by repression of the transcriptional complex that silences the promoter of the UCHL1 gene.

Abstract: The present invention describes methods of molecular diagnosis of a concrete form of a-synucleinopathy, the dementia with Lewy bodies (DLB), associated to the levels of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) or the alteration of its ubiquityl-ligase activity. It also refers to the use of compounds that permit the modification of the UCH-L1 levels or of the enzymatic activity of UCH-L1. This invention has application in the diagnosis and treatment of patients suffering from DLB.

Abstract: A method of nucleic acid analysis includes the stages of synthesizing a first complementary DNA strand from a messenger RNA using compound primers, synthesizing a second DNA strand, labeling by in vitro transcription of an RNA polymerase, and determining the presence of splicing events in the sample. The present invention has application, for example, in analyzing differential splicing events and in diagnosing diseases.

Abstract: Methods and kits are disclosed for determining the methylation of nucleic acids. The methods and kits can be used for the diagnosis and prognosis of diseases. The method and kits can be used to identify biomarkers. The method and kits relate to fragmenting a nucleic acid sample, ligating adaptors to the ends of the nucleic fragments obtained, amplifying the fragments that include both adaptors using specific primers based on the adaptors, labeling of the amplified fragments by in vitro transcription and determining the methylation state of the sample.

Abstract: Method for selectively detecting nucleic acid molecules comprising structural aberrations that are capable of being convented into nicks comprising generating linear nucleic acids from a selected nucleic acid substrate population; denaturing and re-annealing the linear nucleic acids to form nucleic acid duplexes; masking the nucleic acid duplex termini and internal structural aberrations with a masking component; modifying the masked nucleic acids by introducing nicks therein using at least an enzyme possessing endonuclease activity: labelling the modified nucleic acids with labelled nucleotides via nucleic acid nick translation with at least an enzyme displaying a nucleic acid polymerase activity; and selecting and identifying the labelled nucleic acid.

Abstract: Method of analyzing nucleic acids comprising the steps of nucleic acid fractionation, adaptor binding and nucleic acid amplification, and an in vitro transcription step. The invention has application in the field of genomic analysis of organisms by the use of DNA microarrays.

Abstract: The present invention describes methods of molecular diagnosis of a concrete form of a-synucleinopathy, the dementia with Lewy bodies (DLB), associated to the levels of ubiquitin carboxy-terminal hydrolase L1 (UCH-1) or the alteration of its ubiquityl-ligase activity. It also refers to the use of compounds that permit the modification of the UCH-L1 levels or of the enzymatic activity of UCH-L1. This invention has application in the diagnosis and treatment of patients suffering from DLB.

Abstract: The present invention relates to a method for the diagnosis and/or prognosis of Alzheimer's disease by means of determining the DARC gene expression level in a biological sample and comparing said level with a reference value, in which the disturbance of said level is indicative of Alzheimer's disease.

Abstract: The present invention relates to a method for the diagnosis and/or prognosis of Alzheimer's disease by means of determining the ZMIZ1 gene expression level in a biological sample and comparing said level with a reference value, in which the alteration of said level is indicative of Alzheimer's disease.

Abstract: The invention relates to a method for the diagnosis and/or prognosis of Alzheimer's disease, consisting in determining the expression level of a gene encoding a lysosomal marker.

Abstract: The current invention is a novel approach termed “parallel screening” which allows simultaneously screening of a population for insertions in all genes cloned from that or a closely related organism. In order to test this approach, the flowering plant Petunia hybrida was used as a model system. Petunia hybrida line W137 contains a high copy number of the endogenous transposable element dTph1 and has been previously presented as a genetic tool. A 3D library of the plant genomic DNA of 1000 Petunia hybrida W137 plants was generated. The 3D library consists of 30 pools of DNA from 100 plants each. These were used to generate 30 pools of insertion flanking sequences by nested iPCR using a set of transposon-specific primers or by Transposon Display PCR. Insertions into a gene were detected by hybridizing the amplified insertion flanking sequences fixed to a filter with a gene-specific probe, an approach termed simple screening for insertion elements.